Skip to main content
. 2019 Jan 3;33(1):281–287. doi: 10.21873/invivo.11473

Table I. Patient characteristics and median overall survival (OS).

graphic file with name in_vivo-33-283-i0001.jpg

ER, Estrogen receptor; CT, chemotherapy; CMF, cyclophosphamide methotrexate fluorouracil; ET, endocrine therapy; AI, aromatase inhibitor; TAM, tamoxifen; TFI, treatment-free interval; DFI, disease-free interval; 1L, first-line.